Plasma is ineffective in correcting mildly elevated PT-INR in critically ill children: a retrospective observational study by Esther Paula Soundar et al.
Soundar et al. Journal of Intensive Care 2014, 2:64
http://www.jintensivecare.com/content/2/1/64RESEARCH Open AccessPlasma is ineffective in correcting mildly elevated
PT-INR in critically ill children: a retrospective
observational study
Esther Paula Soundar2, Ronald Besandre1, Sarah Kate Hartman1,2, Jun Teruya1,2 and Shiu-Ki Rocky Hui1,2*Abstract
Background: Fresh frozen plasma transfusion is widely utilized in pediatric clinical practice to correct mild
coagulopathy. Several studies on adult population have shown that transfusion of plasma cannot effectively correct
mild coagulopathy when international normalized ratio (INR) is ≤1.5. Much controversy exists about the
generalization of this finding for pediatric populations, especially since pediatric dosages often exceed those in adults.
The aim of this study is to determine the prevalence of plasma transfusion with mild coagulopathy (INR≤ 1.5) and its
effectiveness in a pediatric setting.
Methods: In our tertiary referral hospital, we retrospectively reviewed the electronic medical records of all patients who
received plasma (April to October 2011) for mildly elevated prothrombin time (PT)-INR levels (≤1.5) and had
post-transfusion PT-INR measurements; patients who received intraoperative, ECMO, or plasma exchange-related
plasma transfusions were excluded from this study. We abstracted demographic data and pre- and post
coagulation test results for the patients included in our study.
Results: Among 468 plasma transfusions administered to 285 patients from April to June 2011, 60 plasma
transfusions (12.8%) were given to patients with PT-INR≤ 1.5 (range 1.3–1.5). Forty-one patients [median age
2.5 years (IQR, 0.14 to 13.75 years), median weight of 16.0 kg (IQR, 8.0 to 69.3 kg)] who received 41 single plasma
transfusions [median dose 11 mL/Kg (IQR, 6–15)] had post-transfusion PT-INR measurements and were included in
our study. There was no significant difference in their PT-INR values (p = 0.34) pre- and post-transfusion. Of our
study, only 15.4% patients showed post-transfusion normalization [median change in PT-INR 0.15 (IQR, 0.1–0.2)]
and were not different from the remaining 85% in age, plasma dose, and bleeding status.
Conclusions: The prevalence of plasma transfusion for correction of mildly elevated PT-INR levels in critically ill
children is high (12.8%). Plasma transfusion showed no significant effect in correcting minor prolongation of
PT-INR in pediatric patients regardless of age, volume of plasma transfused per kilogram (dosage), or bleeding status.
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GuidelinesBackground
Fresh frozen plasma (FFP) constitutes a ready supply of
plasma proteins, most notably the coagulation-related
factors. Its utilization resides chiefly in replenishing
coagulation factors in any clinical setting with ongoing
or suspected coagulopathy. As can be expected from a* Correspondence: sxhui@texaschildrens.org
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unless otherwise stated.product with broad indications, plasma usage in the
United States is expanding and evolving along with med-
ical and surgical support capabilities. In particular, studies
of plasma use in pediatric intensive care units (PICUs)
demonstrate more frequent use of plasma to support
volume expansion, massive hemorrhage, liver disease, dis-
seminated intravascular coagulation, and correction of
prolonged clotting tests, among other clinical indications
[1]. Appropriate use of plasma is indicated in massive
hemorrhage, liver disease, and disseminated intravascularl Ltd. This is an Open Access article distributed under the terms of the Creative
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care settings [1,2]. Its role as an effective prophylactic
agent, however, has been disputed when used prior to inva-
sive procedures such as liver biopsy and central line place-
ment, with no correlation found between bleeding risk and
pre-procedure coagulation test results [3,4]. In addition,
plasma transfusion carries its own host of complications,
including disease transmission, allergic reactions, alloim-
munization, volume overload, thrombosis, multiple organ
failure, and transfusion-related acute lung injury (TRALI)
[5-10]. The majority of studies evaluating outcome of
plasma transfusion in specific clinical scenarios, particu-
larly in neonates, have prompted the recent publication of
guidelines to curtail plasma transfusion for mild coagula-
tion abnormalities in children [11]. According to recent
transfusion data issued by hospitals in the United States,
the United Kingdom, and Canada, prescribing plasma
inappropriately is a common practice, despite published
guidelines [12,13].
The current plasma transfusion practice for the pur-
pose of correcting mildly prolonged coagulation tests is
of interest to our institution, the largest pediatric hos-
pital in the United States. Published studies on adult
plasma transfusion have shown minimal to no effect
when used either prophylactically or as a therapeutic
agent for bleeding when the international normalized
ratio (INR) is ≤1.5 [14-16]. Puetz et al. recently demon-
strated pediatric United States hospitals to have a high
prevalence of plasma transfusion in critically ill children
but did not evaluate the indications for transfusion [17].
We set out to evaluate the local transfusion practice
with respect to plasma by: 1) determining the frequency
of plasma transfusions and 2) assessing the significance
of improvements in coagulation tests [prothrombin
time-international normalized ratio (PT-INR)] in the
context of the clinical scenario via the electronic medical
record. In the United States, most transfusion guidelines
are established locally by varying methods within each
institution. However, it is prudent that plasma transfusion
guidelines be based on the aggregate of local, national, and
population-specific evidence. To contribute, we retro-
spectively evaluated the effect of plasma transfusions on
mild elevations of PT-INR often referred to clinically as
“mild coagulopathy”.
Methods
After institutional review board of Baylor College of
Medicine approved the study with waiver of informed
consent, we conducted a retrospective analysis of trans-
fusion and coagulation-related records from the blood
bank and patient electronic medical records (EMR) at
Texas Children’s Hospital for the 3-month time period
from April to June of 2011. Patient chart review was per-
formed to collect demographic and clinical details. Weincluded all patients who: 1) had a pre-transfusion INR
of 1.3 to 1.5, 2) received one or more plasma transfu-
sions, and 3) had a post-transfusion INR checked within
8 h of transfusion. Patients receiving plasma transfusion
support during extracorporeal membranous oxygenation
(ECMO) or as intraoperative transfusion were excluded
from the study. Demographic variables included age,
weight, and patient’s location (excluding emergency
department and operating rooms, all inpatient hospital
units were included). The patient’s clinical description of
disease along with the indication for plasma transfusion
was extracted from the EMR via blood product orders
and provider notes. The results of laboratory coagulation
tests performed on the day of plasma transfusion includ-
ing PT-INR and platelet count were extracted from the
same database. Patient hemostatic conditions were cate-
gorized into bleeding or non-bleeding as documented by
the clinical providers. Next, we assessed any change in the
PT-INR, after plasma transfusion. Independent variables
included age and body weight. PT was measured using
commercial PT reagents on STA-R automatic analyzer
(Diagnostica Stago Inc., Parsippany, NJ, USA).
The patient population was characterized into groups
based on whether PT-INR decreased after plasma trans-
fusion and whether hemostatic status improved (i.e.,
bleeding subsided). Fisher’s exact test was used to assess
the association between two categorical variables such as
post-transfusion decrease in INR (presence or absence),
age (<1 vs. ≥1 month), plasma dose (≤10 vs. >10 cc/kg),
and bleeding symptoms (bleeding vs. non-bleeding). Asso-
ciation between pre-transfusion PT and bleeding was also
assessed. Non-parametric analysis of two related samples
employed the Wilcoxon signed rank test to detect signifi-
cant difference between the pre- and post-transfusion PT-
INR values. Mann–Whitney test allowed determination of
significant difference in different variables between two
categories of patients. In order to determine if an increas-
ing volume of plasma transfused was associated with a
change in INR, patients were divided into quartiles based
on total plasma volume transfused. From this data, a con-
tingency table (4 × 2) analysis was performed and a Chi-
squared (χ2) p value was calculated. P values of <0.05 were
considered statistically significant.
Results
A total of 468 plasma transfusions were administered to
285 patients from April 2011 through June 2011. Among
these, 60 plasma transfusions (12.8%) were given when
PT-INR ≤1.5, ranging from 1.3–1.5. Forty-one patients
had post-transfusion PT-INR measurements. Almost half
(46.3%) of these plasma transfusions were administered
to patients whose PT-INRs were within age-specific nor-
mal levels. Of the 41 patients, 39% of patients (n = 16)
had documented bleeding. Nine patients (22%) were
Table 2 Coagulation parameters pre- and post-transfusion
of plasma for all patients with INR≤1.5
Coagulation test Median (IQR) p valuea
Pre-transfusion PT 16.30 (15.30–17.40) 0.34
Post-transfusion PT 16.40 (14.90–17.40)
Pre-transfusion INR 1.30 (1.20–1.50) 0.42
Post-transfusion INR 1.40 (1.20–1.50)
IQR interquartile range.
aWilcoxon signed rank test.
Table 3 Baseline characteristics of patients with and
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ing symptoms. Characteristics of patients (n = 41) with
plasma transfusion for mildly prolonged PT-INR are
listed in Table 1.
There was no statistically significant difference in PT-
INR before and after plasma transfusion in the study
population (p = 0.34) (Table 2). Transfusion of plasma
resulted in normalization of PT-INR values in only
15.4% (n = 6) of patients with the remainder showing no
improvement in PT-INR. Table 3 describes the charac-
teristics of these patients. The median change in PT-INR
for patients with normalization was 0.15 (IQR, 0.1–0.2).
There was no statistically significant association between
PT-INR normalization and higher plasma dose, younger
age, or bleeding status (p = 0.18, p = 0.16, p = 0.68), re-
spectively. Increasing plasma transfusion dose was not
associated with a change in INR (p = 0.78).
Thirty-nine percent (n = 16) of patients were trans-
fused with plasma during a bleeding episode. There was
no significant association between pre-transfusion PT
and bleeding (p = 0.70). Among these patients, the ma-
jority (69%, n = 11) were clinically deemed as mild: e.g.,
bleeding around the gums (n = 2), slow oozing from an
incision site (n = 2), a small amount of blood in the
endotracheal and nasogastric tube (n = 2) and blood-
tinged chest-tube output (n = 5). The remaining five pa-
tients had clinically significant bleeding such as melena
(n = 2), hemoptysis (n = 2), and epistaxis (n = 1). Four out
of 16 (25%) patients showed improvement in bleeding,
and it stopped in 2 out of 4 after local use of anti-
fibrinolytics. Of all the bleeding patients, 12% had an im-
provement in PT-INR values, but were not normalized.
Bleeding status was not associated with post-transfusion
change in PT-INR (p = 1.0). Platelet counts were above
100,000/mL in both bleeding and non-bleeding patients
(p = 0.74). The volume and dosage of plasma administered
to bleeders and non-bleeders were not different (p = 0.65,
p = 0.85) (Table 4).
Discussion
Despite the results of many clinical studies, clinicians
still prefer to use plasma as a therapeutic or prophylactic
measure to correct mildly prolonged PT-INR based onTable 1 Characteristics of patients (n = 41) with plasma
transfusion for mildly prolonged PT-INR
Dependent variable Median IQR
Age, years 5.00 (0.83–14.00)
Weight, kg 19.00 (8.80–70.80)
Platelet count 121 (73–176)
Volume of plasma transfused, mL 170 (115–333)
Plasma dose, mL/kg 11 (6–15)
IQR interquartile range.assumptions of reducing bleeding risk [15]. In our study,
we sought to assess the prevalence of plasma use in
pediatric inpatients and found it to be high (12.8%). Among
our study population, close to half (42%) were less than
1 year old. A majority of these transfusions occurred in the
ICU setting including the cardiovascular, neonatal, and
pediatric ICUs. This is consistent with a recent large epi-
demiological study describing the pattern of plasma usage
in pediatric hospitals [17]. Our data illustrates the extent
of ineffective use of plasma in neonates and in critically ill
children, including those with cardiac diseases. Although
targeted and therapeutic plasma use in certain clinical
conditions can be life-saving (e.g., support of coagulopa-
thy), its general prophylactic benefit in critically ill chil-
dren is highly doubtful and lacks evidence. In the absence
of evidence-based guidelines, pediatric intensivists and
physicians in other specialties must make decisions based
on presumed probability of benefit to the patient.
In our study, only 39% of patients had bleeding symp-
toms; the majority (69%) had bleeding events considered
mild due to location and very small volume of blood loss.
This demonstrates that over half of the patient population
with a mild elevation in PT-INR received plasma for non-
bleeding causes. Frequent reasons cited in the EMR
include pre-procedural prophylaxis and primary volume
replacement. The platelet counts were similar in both
bleeding and non-bleeding patients indicating that
thrombocytopenia was unlikely to have increased concern
for overall coagulopathy and therefore lowered the thresh-
old for plasma transfusion. We found no significant asso-
ciation between pre-transfusion PT-INR and bleeding.without normalization of PT-INR





Age, years 1.25 (0.08–13.0) 7.5 (3.0–14.0) 0.15
Weight, kg 14.9 (7.7–61.6) 44.9 (16.8–70.8) 0.14
Volume of plasma
transfused, mL
168 (90–302) 180 (130–250) 0.82
Plasma dose, mL/Kg 12 (6–16) 5 (2–10) 0.06
Platelet count × 103 124 (74–182) 87 (54–120) 0.16
Values are expressed in median (interquartile range).
aMann–Whitney test.









Transfusion dose, mL/kg 11 (3–14) 12 (10–17) 0.85
Transfusion volume, mL 203 (90–421) 159 (115–248) 0.65
PT, s 16.3 (15.2–17.6) 16.3 (15.4–17.2) 0.85
Platelet count × 103/mL 116 (74–175) 124 (78–174) 0.74
Values expressed in median (interquartile range).
aMann–Whitney test.
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transfusion include: correction of coagulopathy related to
DIC, vitamin K, and inherited deficiencies of clotting
factors resulting in bleeding [1]. However, our findings
and experience suggest that plasma transfusion to attempt
correction of an INR <1.5 is a common practice. Although
it is not well-documented in the literature, there is a com-
mon assumption albeit false that a small increase in INR
will reliably predict bleeding risk and that clotting factors
in plasma will correct this “derangement” and protect
from bleeding. Additionally, there are no pediatric ran-
domized control studies on mild elevation of INR during
procedures that offer definite evidence of predictive ability
with respect to bleeding. It is also critical, when evaluating
hemostasis in neonates, that age-specific normal ranges
are determined and referenced. In our study, neonates
received 22% (9/41) of transfusions, only half of those with
bleeding or potential coagulopathy. Pre-transfusion INR
values were all within age-specific normal ranges. It is
not surprising that none of these patients had a post-
transfusion change in INR. In comparison to adult
coagulation times, neonates normally have “more pro-
longed” coagulation times. The prolongation is usually
mild and is not considered pathologic or carrying in-
creased risk of bleeding. Therefore, mildly abnormal co-
agulation tests without bleeding or strong clinical
indicators of coagulopathy should be confirmed abnor-
mal for age and are not an independent indication for
plasma therapy in neonates [18].
Our study of pediatric patients [5 (0.14–13.75) median
age (IQR) years] examined the effect of plasma transfu-
sion on PT-INR. We found that of the 16% of patients
with a post-plasma transfusion change in PT-INR, the
change was negligible regardless of increasing dose. We
found no significant association between pre-transfusion
PT and bleeding. Abdel-Wahab et al. report that plasma
corrected INR in only about 16% of adult ICU patients
with initial mild elevation in PT-INR in Massachusetts
General Hospital [19]. Holland et al. also found insignifi-
cant changes in INR results in both pediatric and adult
study populations receiving plasma for INR elevations
≤1.5 [20]. Segal et al. systematically reviewed multiplestudies and found inadequate proof to determine that
abnormal coagulation test results predict bleeding [16].
In a recent review of prophylactic “correction” of INR
prior to neurosurgery, the authors concluded that there is
no added benefit of plasma transfusion in a non-bleeding
patient with mildly prolonged INR [14]. A systematic re-
view published in 2005 identified 25 adult studies, among
which none found an association of mildly prolonged co-
agulation variables with increased risk of bleeding [16].
Thirty percent coagulation factor activity is necessary for
maintaining hemostasis. However, Burns et al. demon-
strated that prolongation in INR occurs at 50% reduction
of multiple coagulation factor activity [21]. Due to assay
design and potential interfering clinical factors, PT-INR is
an insensitive predictor of low factor levels in critically ill
adults, which in part explains their inability to predict
bleeding [22].
This study is among very few in the pediatric literature
that addresses effectiveness of plasma transfusion for
mildly prolonged PT-INR. The results of our study are
based on retrospective data, which has an inherent disad-
vantage in documentation. However, this issue is some-
what mitigated by the bulk of the study being focused on
the pre- and post-transfusion delta in INR, which is easily
and accurately mined from the laboratory information sys-
tem or EMR. For a future study with more emphasis on
outcomes, we would include a non-transfused patient con-
trol group with mildly prolonged coagulation tests for out-
come comparison, e.g., peri- or post-procedural bleeding.
However, our results signify the effect of plasma transfu-
sion in pediatric patients: plasma transfusion does not sig-
nificantly improve mildly prolonged PT-INR. This applies
to bleeding and non-bleeding patients with the exception
of a rapidly bleeding or evolving coagulopathic scenario.
In these settings, a mild abnormality may become a ser-
ious deficiency during the lag time between specimen
collection and reporting of results. Guidelines on the
appropriateness of plasma transfusion, as well as relevant
test limitations, should be evidence-based when those
tests are used as transfusion triggers. Optimal patient care
requires pediatric critical care physicians to be aware of
low-to-no benefit and potential harm of plasma therapy
for mild coagulation abnormalities without supporting in-
dications. Further research, including randomized control
trials, is necessary to provide robust evidence for guiding
plasma use in children.
Conclusion
Plasma transfusion in critically ill children does not signifi-
cantly correct mildly prolonged PT-INR. Pediatric intensi-
vists should avoid prescribing plasma transfusion for an
isolated mild increase in PT-INR values with an aim of pre-
venting or controlling bleeding episodes. Guidelines to
optimize its use should be formulated based on prospective
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transfusion triggers and outcomes related to both bleeding
and adverse transfusion reactions.
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